Mesirow Financial Investment Management Inc. Sells 597 Shares of Intuitive Surgical, Inc. (NASDAQ:ISRG)

Key Points

• Mesirow Financial Investment Management Inc. has reduced its holdings in Intuitive Surgical, Inc. by 47.9%, now owning 649 shares after selling 597 shares during the first quarter.
• Insider transactions indicate significant activity, with executives like Mark Brosius and Myriam Curet selling shares and reducing their ownership substantially over recent months.
• Intuitive Surgical has a current market capitalization of $173.19 billion and has recently exceeded earnings expectations, reporting a revenue of $2.44 billion for the last quarter.

Mesirow Financial Investment Management Inc. decreased its stake in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG - Free Report) by 47.9% during the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 649 shares of the medical equipment provider's stock after selling 597 shares during the quarter. Mesirow Financial Investment Management Inc.'s holdings in Intuitive Surgical were worth $321,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in ISRG. Chilton Capital Management LLC increased its position in shares of Intuitive Surgical by 614.3% during the 1st quarter. Chilton Capital Management LLC now owns 50 shares of the medical equipment provider's stock worth $25,000 after purchasing an additional 43 shares during the last quarter. Parvin Asset Management LLC acquired a new position in shares of Intuitive Surgical during the 4th quarter worth approximately $26,000. Global Financial Private Client LLC increased its holdings in shares of Intuitive Surgical by 253.3% during the 1st quarter. Global Financial Private Client LLC now owns 53 shares of the medical equipment provider's stock worth $26,000 after acquiring an additional 38 shares during the last quarter. Elite Financial Inc. acquired a new position in shares of Intuitive Surgical during the 1st quarter worth approximately $26,000. Finally, Hurley Capital LLC acquired a new position in shares of Intuitive Surgical during the 4th quarter worth approximately $28,000. Institutional investors and hedge funds own 83.64% of the company's stock.

Intuitive Surgical Stock Performance

Shares of ISRG stock traded up $0.24 on Monday, hitting $483.36. The company had a trading volume of 2,493,317 shares, compared to its average volume of 2,146,593. The firm has a market cap of $173.27 billion, a P/E ratio of 67.41, a P/E/G ratio of 5.06 and a beta of 1.59. The stock's 50-day moving average is $524.01 and its two-hundred day moving average is $532.67. Intuitive Surgical, Inc. has a twelve month low of $425.00 and a twelve month high of $616.00.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) last issued its quarterly earnings results on Tuesday, July 22nd. The medical equipment provider reported $2.19 earnings per share for the quarter, beating the consensus estimate of $1.93 by $0.26. The company had revenue of $2.44 billion during the quarter, compared to analysts' expectations of $2.35 billion. Intuitive Surgical had a return on equity of 14.56% and a net margin of 28.51%. The business's quarterly revenue was up 21.4% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.78 earnings per share. Equities research analysts predict that Intuitive Surgical, Inc. will post 6.43 EPS for the current year.

Insider Buying and Selling

In related news, SVP Mark Brosius sold 216 shares of the firm's stock in a transaction that occurred on Friday, June 6th. The stock was sold at an average price of $563.11, for a total transaction of $121,631.76. Following the completion of the sale, the senior vice president owned 907 shares of the company's stock, valued at $510,740.77. This trade represents a 19.23% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Gary S. Guthart sold 2,800 shares of the firm's stock in a transaction that occurred on Monday, July 28th. The stock was sold at an average price of $495.24, for a total value of $1,386,672.00. Following the sale, the insider directly owned 18,520 shares of the company's stock, valued at $9,171,844.80. This represents a 13.13% decrease in their position. The disclosure for this sale can be found here. Insiders sold 15,903 shares of company stock valued at $7,932,778 over the last 90 days. Company insiders own 0.70% of the company's stock.

Wall Street Analysts Forecast Growth

ISRG has been the topic of a number of recent analyst reports. Wells Fargo & Company boosted their target price on Intuitive Surgical from $559.00 to $599.00 and gave the stock an "overweight" rating in a report on Wednesday, July 23rd. Barclays decreased their target price on Intuitive Surgical from $684.00 to $635.00 and set an "overweight" rating on the stock in a report on Thursday, April 24th. BTIG Research boosted their target price on Intuitive Surgical from $566.00 to $571.00 and gave the stock a "buy" rating in a report on Wednesday, July 23rd. Robert W. Baird reduced their price target on Intuitive Surgical from $600.00 to $575.00 and set an "outperform" rating for the company in a research note on Wednesday, April 23rd. Finally, Wall Street Zen upgraded Intuitive Surgical from a "hold" rating to a "buy" rating in a research note on Saturday, July 26th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and fourteen have assigned a buy rating to the company's stock. According to data from MarketBeat, Intuitive Surgical currently has a consensus rating of "Moderate Buy" and a consensus price target of $595.95.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.